/
PROK
$1.89+$0.06 (+3.28%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$375.5M
205M shares
52-week range
$0.54 – $7.13
20% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
17.98%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-6.74
ProKidney Corp. Class A Ordinary Shares
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
www.prokidney.com- Employees
- 231
- IPO / List date
- Jul 12, 2022
- HQ
- WINSTON-SALEM, NC
Held by traders on TradeandTell
No one on the platform currently holds PROK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,250,794 | $2.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PROK yet.
